机构：[1]Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis, National Clinical Research Center for Digestive Diseases, Beijing, China首都医科大学附属北京友谊医院[2]Department of Hepatology, First Hospital of Jilin University, Changchun, Jilin, China[3]Department of Infectious Diseases, Henan Provincial People’s Hospital, Zhengzhou, Henan, China[4]Center of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China[5]Department of Infectious Diseases, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China[6]Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou, Gansu, China[7]Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China[8]Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, Sichuan, China四川大学华西医院[9]Department of Gastroenterology and Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, China[10]Center of Infectious Diseases, The Third People’s Hospital of Taiyuan, Taiyuan, Shanxi, China[11]Department of Traditional and Western Medical Hepatology, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China[12]Department of Infectious Diseases, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China中国医科大学附属盛京医院中国医科大学盛京医院[13]Department of Hepatology, Tianjin Third Central Hospital, Tianjin Medical University, Tianjin, China[14]Department of Hepatology, Lanzhou University Second Hospital, Lanzhou, Gansu, China[15]Department of Infectious Diseases, Peking Union Medical College Hospital, Beijing, China[16]Department of Infectious Diseases, The Affiliated Hospital of Southwest Medical University, Luzhou, Gansu, China[17]Department of Gastroenterology, Shanghai Public Health Clinical Center, Shanghai, China[18]Department of Hepatology, Xinjiang Uygur Autonomous Region Traditional Chinese Medicine Hospital, Urumqi, Xinjiang, China[19]Department of Infectious Diseases, Shanghai Ruijin Hospital, Jiao Tong University School of Medicine, Shanghai, China[20]Department of Infectious Diseases, The First Affiliated Hospital of Xian Jiao Tong University, Xi’an, Shaanxi, China[21]Department of Infectious Diseases, Xiangya Hospital Central South University, Changsha, Hunan, China[22]Department of Digestive System, Beijing Tiantan Hospital, Capital Medical University, Beijing, China首都医科大学附属天坛医院[23]Department of Infectious Diseases,Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China[24]Department of Infectious Diseases, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China昆明医科大学附属第一医院[25]Department of Infectious Diseases, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Henan, China[26]Department of Infectious Diseases, Yanbian University Hospital, Yanji, Jilin, China[27]Department of Infectious Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China重庆医科大学附属第一医院[28]Department of Hepatology, The Fourth People’s Hospital of Qinghai Province, Xining, Qinghai, China[29]Department of Infectious Diseases, Xinjiang Changji Prefecture People’s Hospital, Changji, Xinjiang, China[30]Department of Hepatopancreatobiliary Surgery, Affiliated Hospital of Weifang Medical University, Weifang, Shandong, China[31]Department of Hepatology, Hunan Provincial People’s Hospital, Changsha, Hunan, China[32]Department of Gastroenterology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China[33]Department of Hepatology, Xixi Hospital of Hangzhou, Hangzhou, Zhejiang, China[34]Department of Infectious Diseases, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China[35]Department of Infectious Diseases, Union Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China华中科技大学同济医学院附属协和医院[36]Department of Hepatopancreatobiliary and Splenic Medicine, The Affiliated Hospital, Logistics University of People’s Armed Police Force, Tianjin, China[37]Department of Infectious Diseases, Infectious Disease Hospital of Wuhai, Wuhai, Inner Mongolia, China[38]Department of Infectious Diseases, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China[39]Department of Infectious Diseases, The First Affiliated Hospital of Shanxi Medical University, Taiyuan, Shanxi, China[40]Department of Infectious Diseases, The Fifth Hospital of Shijiazhuang, Shijiazhuang, Hebei, China[41]Department of Infectious Diseases, Guizhou Provincial People’s Hospital, Guiyang, Guizhou, China[42]Department of Infectious Diseases, Hainan General Hospital, Haikou, Hainan, China[43]Department of Infectious Diseases, The Second Hospital of Shandong University, Jinan, Shandong, China[44]Department of Infectious Diseases, Yanan University Affiliated Hospital, Yan’an, Shaanxi, China[45]Department of Infectious Diseases, Peking University First Hospital, Beijing, China[46]Peking University Hepatology Institute, Peking University People’s Hospital, Beijing, China[47]Institute of Hepatology and Department of Infectious Disease, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China[48]Artificial Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing, China[49]Department of Microbiology and Infectious Disease Center, Peking University Health Science Center, Beijing, China[50]The China Foundation of Hepatitis Prevention and Control, Beijing China[51]Center for Clinical Epidemiology and EBM, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Center for Digestive Diseases, Beijing, China首都医科大学附属北京友谊医院
Background and Aims: Chronic hepatitis B virus (HBV) infection remains a major public health problem globally. Here, we describe the baseline characteristics and treatment profiles of HBV-infected patients recruited to the China Registry of Hepatitis B. Methods: Inclusion criteria were patients with different stages of chronic HBV infection and complete key data. Exclusion criteria were patients with hepatocellular carcinoma. The baseline clinical, laboratory and treatment profiles were analyzed. Results: Finally, 40,431 patients were included. The median age was 43 years, with 65.2% being men and 51.3% being positive for hepatitis B e antigen (HBeAg). The most common initial diagnosis was chronic hepatitis B (81.0%), followed by cirrhosis (9.3%), inactive carrier of hepatitis B surface antigen (HBsAg) (6.7%), and immune tolerant phase of hepatitis B infection (3.0%). Among the 21,228 patients who were on treatment, 88.0%, 10.0% and 2.0% received nucleos(t)ide analogues (NAs), interferon or combination of NAs and interferon, respectively. The proportion of patients who received preferred NAs (entecavir or tenofovir disoproxil fumarate) had increased from 13.5% in 2003 to 79.7% in 2016. Conclusions: We concluded that middle-aged men accounted for most of the patients with chronic hepatitis B in this cross-sectional study. About half of the patients were HBeAg-positive. NAs were the most commonly used therapy, and use of the preferred NAs had steadily increased in the past decade.
基金：
We thank the China Foundation for Hepatitis Prevention and
Control, Chinese Society of Hepatology, Chia Tai-Tianqing
Pharmaceutical Group Co., Ltd and Shanghai Ashermed
Healthcare Communications, Ltd, for their administrative coordination, technical assistance, and unrestricted grant to
the CR-HepB and this paper.
第一作者机构：[1]Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis, National Clinical Research Center for Digestive Diseases, Beijing, China
通讯作者：
通讯机构：[1]Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis, National Clinical Research Center for Digestive Diseases, Beijing, China[51]Center for Clinical Epidemiology and EBM, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Center for Digestive Diseases, Beijing, China[*1]Liver Research Center, Beijing Friendship Hospital, Capital Medical University, 95 Yong-an Road, Xicheng District, Beijing 100050, China.[*2]Center for Clinical Epidemiology and EBM, Beijing Friendship Hospital, Capital Medical University, 95 Yong-an Road, Xicheng District, Beijing 100050, China.
推荐引用方式(GB/T 7714)：
Shan Shan,Hong You,Junqi Niu,et al.Baseline Characteristics and Treatment Patterns of the Patients Recruited to the China Registry of Hepatitis B[J].JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY.2019,7(4):322-328.doi:10.14218/JCTH.2019.00052.
APA：
Shan Shan,Hong You,Junqi Niu,Jia Shang,Wen Xie...&the CR-HepB study group,Beijing,China.(2019).Baseline Characteristics and Treatment Patterns of the Patients Recruited to the China Registry of Hepatitis B.JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY,7,(4)
MLA：
Shan Shan,et al."Baseline Characteristics and Treatment Patterns of the Patients Recruited to the China Registry of Hepatitis B".JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY 7..4(2019):322-328
